HYLOMORPH, an ETH Zurich spin-off and Medtech startup, closes its Series A financing round with CHF 3.2 million.
The funding will allow the startup company to finalize product development and conduct clinical studies required for FDA approval and CE certification expected in 2021.
hemotune, Seervision and Wingtra have been selected for H2020 SME Instrument Phase I funding. Each project supported by the SME Instrument will receive €50.000 to draft a business plan and validate...
Seervision wins the most important technology prize for innovation and technology transfer in Switzerland in the category Inventors.
HYLOMORPH has won first place at the 2019 EHRA Innovations Awards, which took place at the European Heart Rhythm Association (EHRA) conference in Lisbon.